+ Community
Gene Johnson | Mar 9, 2017

Aurinia Pharmaceuticals CEO speaks at health care conference

Aurinia Pharmaceuticals Inc. CEO Richard M. Glickman recently spoke at the Cowen and Company 37th Annual Healthcare Conference in Boston.

The company is a clinical stage biopharmaceutical business that is focused on developing and commercializing therapies that treat patients suffering from serious diseases who have a high unmet medical need.

Aurinia Pharmaceuticals is in the process of developing the investigational drug voclosporin, which will be used in the treatment of lupus nephritis. Lupus nephritis is inflammation of the kidney as a result of systemic lupus erythematosus. It shows a serious progression of the disease.

A webcast was recorded and can be accessed at www.auriniapharma.com.

Organizations in this story

More News